Ladenburg Thalmann analyst Matthew Kaplan maintains $Axsome Therapeutics (AXSM.US)$ with a buy rating, and adjusts the target price from $173 to $175.
According to TipRanks data, the analyst has a success rate of 47.0% and a total average return of 13.6% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Axsome Therapeutics (AXSM.US)$'s main analysts recently are as follows:
Following a third-quarter update that presented a revenue surpassing expectations and positive developments in the pipeline, sentiments on Axsome Therapeutics remain optimistic. Clarifications regarding the schedule of two concurrent Phase 3 Auvelity ADA trials have delineated the timeline for upcoming catalyst events, with expectations for simultaneous study outcomes in the fourth quarter. It's believed that achieving success in either one of the two ADA trials would be sufficient to dispel any lingering concerns about the regulatory outlook for this significant label expansion.
The third quarter of 2024 saw robust performance, largely driven by a significant increase in Auvelity sales. The company remains a favored choice due to the anticipation of several key events that could positively influence its stock by the close of the fourth quarter of 2024.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
Ladenburg Thalmann分析师Matthew Kaplan维持$Axsome Therapeutics (AXSM.US)$买入评级，并将目标价从173美元上调至175美元。
根据TipRanks数据显示，该分析师近一年总胜率为47.0%，总平均回报率为13.6%。
此外，综合报道，$Axsome Therapeutics (AXSM.US)$近期主要分析师观点如下：
在第三季度的更新中，营业收入超出预期，管线中的积极进展使得市场对axsome therapeutics的情绪依然乐观。关于两个并行的第三阶段Auvelity ADA试验的时间表的澄清，已划定即将发生的催化剂事件的时间线，预计在第四季度同时公布研究结果。人们普遍认为，在两个ADA试验中成功实现任何一个将足以消除对这一重要标签扩展的监管前景的任何 lingering concerns。
2024年第三季度表现强劲，主要得益于Auvelity销售的显著增长。由于预期有几个关键事件可能在2024年第四季度结束时对其股票产生积极影响，该公司仍然是一个受到青睐的选择。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
